Bill > HB417

This bill amends Maryland's criminal law to classify medetomidine and xylazine as Schedule III controlled dangerous substances, meaning they are recognized as having a potential for abuse, accepted medical use in treatment in the United States, and a moderate to low risk of physical dependence or high psychological dependence. In addition to this reclassification, the bill prohibits retailers from selling or distributing medetomidine or xylazine products to anyone under 21 years old and requires proof that the intended use is for institutional, veterinary, or scientific purposes. Retailers are also mandated to keep records of these sales, including proof of age and intended use, and face civil penalties for violations, with funds from these penalties going to the Maryland Substance Abuse Fund. This legislation is set to take effect on October 1, 2026.